1-(2,3-di(thiophen-2-yl)quinoxalin-6-yl)-3-(2-methoxyethyl)urea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-(2,3-di(thiophen-2-yl)quinoxalin-6-yl)-3-(2-methoxyethyl)urea
• 英文别名: 1-(2,3-dithiophen-2-ylquinoxalin-6-yl)-3-(2-methoxyethyl)urea
• 化学式: C₂₀H₁₈N₄O₂S₂
• 分子量: 410.521
• InChiKey: CTPVNWVUAGMHEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  133
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,3-di(thiophen-2-yl)quinoxalin-6-amine 、 2-甲氧基乙胺 在 三光气 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 以50%的产率得到1-(2,3-di(thiophen-2-yl)quinoxalin-6-yl)-3-(2-methoxyethyl)urea
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS FOR INHIBITING ACSS2
  [FR] COMPOSITIONS ET MÉTHODES POUR INHIBER ACSS2

  摘要：

  本发明提供了抑制ACSS2以调节组蛋白乙酰化或用于治疗或预防神经系统疾病或紊乱的组合物和方法。

  公开号：

  WO2020069093A1

文献信息

• [EN] ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME<br/>[FR] INHIBITEURS DE L'ACÉTYL-COA SYNTHÉTASE 2 (ACSS2) ET LEURS PROCÉDÉS D'UTILISATION
  申请人：THE WISTAR INST

  公开号：WO2020252407A1

  公开（公告）日：2020-12-17

  The present disclosure provides compounds that are ACSS2 inhibitors. In certain embodiments, the compounds of the disclosure are useful for treating and/or preventing certain types of cancer.

  本公开提供了一些ACSS2抑制剂化合物。在某些实施例中，本公开的化合物可用于治疗和/或预防某些类型的癌症。
• COMPOSITIONS AND METHODS FOR INHIBITING ACSS2
  申请人：The Trustees of The University of Pennsylvania

  公开号：EP3687628A1

  公开（公告）日：2020-08-05
• ACETYL-COA SYNTHETASE 2 (ACSS2) INHIBITORS AND METHODS USING SAME
  申请人：The Wistar Institute

  公开号：EP3983391A1

  公开（公告）日：2022-04-20
• ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT
  申请人：Severson Bill

  公开号：US20130085133A1

  公开（公告）日：2013-04-04

  The present disclosure relates to novel compounds of formulas (1) through (19) and to a method for treating humans infected with a virus including various respiratory viruses such as members of the Paramyxoviridae family (respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human parainfluenza virus (HPIV), measles virus, and mumps virus) with a compound of formulas (1) through (19). The present disclosure also relates to a cytopathic effect (CPE)-based assay that will assess virus-induced CPE for screening of compounds for treating viral diseases or inhibiting a virus.
• CANNABIDIOL DERIVATIVES AS INHIBITORS OF THE HIF PROLYL HYDROXYLASES ACTIVITY
  申请人：Emerald Health Pharmaceuticals Inc.

  公开号：US20210317070A1

  公开（公告）日：2021-10-14

  Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol quinol derivatives of Formula (I), and compositions comprising the same, show thus capacity to inhibit PHD activities and, as a result, stabilize the HIF-1α and HIF-2α levels, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, regulate HIF-dependent gene expression in different cell types and induce collagen contraction. Said cannabidiol quinol derivatives of Formula (I) are useful in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity such as stroke, traumatic injuries anemia, myocardial ischaemia-reperfusion injury, acute lung injury, infectious diseases, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.